This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl. Active years: 2019-2022.
Location History:
- Congleton, GB (2019)
- Slough, GB (2022)
Company Filing History:
Years Active: 2019-2022
Title: Adam Samuel Platt: Innovator in Biomarker Research
Introduction
Adam Samuel Platt is a notable inventor based in Congleton, GB. He has made significant contributions to the field of biomarker research, particularly in relation to IL-17 mediated diseases. With a total of 2 patents, his work has the potential to impact therapeutic approaches in this area.
Latest Patents
Platt's latest patents include the invention titled "Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy." This invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy. This innovative approach could enhance the effectiveness of treatments for patients suffering from these conditions.
Career Highlights
Throughout his career, Adam Samuel Platt has worked with prominent companies such as UCB Biopharma Sprl and UCB Biopharma Srl. His experience in these organizations has contributed to his expertise in the field of biomarker research and development.
Collaborations
Some of his notable coworkers include Stephen Edward Rapecki and Mara Fortunato. Their collaboration has likely fostered a productive environment for innovation and research.
Conclusion
Adam Samuel Platt is a distinguished inventor whose work in biomarker research is paving the way for advancements in IL-17 mediated therapies. His contributions are significant and hold promise for future medical applications.